|
1
|
Farber HW, Miller DP, Poms AD, Badesch DB,
Frost AE, Muros-Le Rouzic E, Romero AJ, Benton WW, Elliott CG,
McGoon MD and Benza RL: Five-Year outcomes of patients enrolled in
the REVEAL Registry. Chest. 148:1043–1054. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Simonneau G, Gatzoulis MA, Adatia I,
Celermajer D, Denton C, Ghofrani A, Sanchez MA Gomez, Kumar R
Krishna, Landzberg M, Machado RF, et al: Updated clinical
classification of pulmonary hypertension. J Am Coll Cardiol. 62 25
Suppl:D34–D41. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Opitz C, Rosenkranz S, Ghofrani HA, Grunig
E, Klose H, Olschewski H and Hoeper M: ESC guidelines 2015
pulmonary hypertension: Diagnosis and treatment. Dtsch Med
Wochenschr. 141:1764–1769. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hurdman J, Condliffe R, Elliot CA, Davies
C, Hill C, Wild JM, Capener D, Sephton P, Hamilton N, Armstrong IJ,
et al: ASPIRE registry: Assessing the spectrum of pulmonary
hypertension identified at a REferral centre. Eur Respir J.
39:945–955. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thompson AA and Lawrie A: Targeting
Vascular remodeling to treat pulmonary arterial hypertension.
Trends Mol Med. 23:31–45. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chelladurai P, Seeger W and Pullamsetti
SS: Matrix metalloproteinases and their inhibitors in pulmonary
hypertension. Eur Respir J. 40:766–782. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Morrell NW, Atochina EN, Morris KG,
Danilov SM and Stenmark KR: Angiotensin converting enzyme
expression is increased in small pulmonary arteries of rats with
hypoxia-induced pulmonary hypertension. J Clin Invest.
96:1823–1833. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Orte C, Polak JM, Haworth SG, Yacoub MH
and Morrell NW: Expression of pulmonary vascular
angiotensin-converting enzyme in primary and secondary plexiform
pulmonary hypertension. J Pathol. 192:379–384. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
de Man FS, Tu L, Handoko ML, Rain S,
Ruiter G, Francois C, Schalij I, Dorfmuller P, Simonneau G, Fadel
E, et al: Dysregulated renin-angiotensin-aldosterone system
contributes to pulmonary arterial hypertension. Am J Respir Crit
Care Med. 186:780–789. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Morrell NW, Higham MA, Phillips PG, Shakur
BH, Robinson PJ and Beddoes RJ: Pilot study of losartan for
pulmonary hypertension in chronic obstructive pulmonary disease.
Respir Res. 6:882005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rondelet B, Kerbaul F, van Beneden R,
Hubloue I, Huez S, Fesler P, Remmelink M, Brimioulle S, Salmon I
and Naeije R: Prevention of pulmonary vascular remodeling and of
decreased BMPR-2 expression by losartan therapy in shunt-induced
pulmonary hypertension. Am J Physiol Heart Circ Physiol.
289:H2319–H2324. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xie L, Lin P, Xie H and Xu C: Effects of
atorvastatin and losartan on monocrotaline-induced pulmonary artery
remodeling in rats. Clin Exp Hypertens. 32:547–554. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Okada M, Harada T, Kikuzuki R, Yamawaki H
and Hara Y: Effects of telmisartan on right ventricular remodeling
induced by monocrotaline in rats. J Pharmacol Sci. 111:193–200.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Saygili E, Rana OR, Saygili E, Reuter H,
Frank K, Schwinger RH, Muller-Ehmsen J and Zobel C: Losartan
prevents stretch-induced electrical remodeling in cultured atrial
neonatal myocytes. Am J Physiol Heart Circ Physiol.
292:H2898–H2905. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ridker PM, Danielson E, Rifai N and Glynn
RJ: Val-MARC Investigators: Valsartan, blood pressure reduction and
C-reactive protein: Primary report of the Val-MARC trial.
Hypertension. 48:73–79. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Anand IS, Kuskowski MA, Rector TS, Florea
VG, Glazer RD, Hester A, Chiang YT, Aknay N, Maggioni AP, Opasich
C, et al: Anemia and change in hemoglobin over time related to
mortality and morbidity in patients with chronic heart failure:
Results from Val-HeFT. Circulation. 112:1121–1127. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Croom KF and Keating GM: Valsartan: A
review of its use in patients with heart failure and/or left
ventricular systolic dysfunction after myocardial infarction. Am J
Cardiovasc Drugs. 4:395–404. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
National Research Council (US) Committee
for the update of the guide for the care and use of laboratory
animals: Guide for the care and use of laboratory animals. 8th.
National Academies Press; Washington, DC: 2011
|
|
19
|
Xu D, Guo H, Xu X, Lu Z, Fassett J, Hu X,
Xu Y, Tang Q, Hu D, Somani A, et al: Exacerbated pulmonary arterial
hypertension and right ventricular hypertrophy in animals with loss
of function of extracellular superoxide dismutase. Hypertension.
58:303–309. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen Y, Guo H, Xu D, Xu X, Wang H, Hu X,
Lu Z, Kwak D, Xu Y, Gunther R, et al: Left ventricular failure
produces profound lung remodeling and pulmonary hypertension in
mice: Heart failure causes severe lung disease. Hypertension.
59:1170–1178. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pacher P, Nagayama T, Mukhopadhyay P,
Bátkai S and Kass DA: Measurement of cardiac function using
pressure-volume conductance catheter technique in mice and rats.
Nat Protoc. 3:1422–1434. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fan YF, Zhang R, Jiang X, Wen L, Wu DC,
Liu D, Yuan P, Wang YL and Jing ZC: The phosphodiesterase-5
inhibitor vardenafil reduces oxidative stress while reversing
pulmonary arterial hypertension. Cardiovasc Res. 99:395–403. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Abe K, Shimokawa H, Morikawa K, Uwatoku T,
Oi K, Matsumoto Y, Hattori T, Nakashima Y, Kaibuchi K, Sueishi K
and Takeshit A: Long-term treatment with a Rho-kinase inhibitor
improves monocrotaline-induced fatal pulmonary hypertension in
rats. Circ Res. 94:385–393. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cassis LA, Rippetoe PE, Soltis EE, Painter
DJ, Fitz R and Gillespie MN: Angiotensin II and
monocrotaline-induced pulmonary hypertension: Effect of losartan
(DuP 753), a nonpeptide angiotensin type 1 receptor antagonist. J
Pharmacol Exp Ther. 262:1168–1172. 1992.PubMed/NCBI
|
|
25
|
Destro M, Cagnoni F, D'Ospina A, Ricci AR,
Demichele E, Peros E, Zaninelli A and Preti P: Role of valsartan,
amlodipine and hydrochlorothiazide fixed combination in blood
pressure control: An update. Vasc Health Risk Manag. 6:253–260.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lesogor A, Cohn JN, Latini R, Tognoni G,
Krum H, Massie B, Zalewski A, Kandra A, Hua TA and Gimpelewicz C:
Interaction between baseline and early worsening of renal function
and efficacy of renin-angiotensin-aldosterone system blockade in
patients with heart failure: Insights from the Val-HeFT study. Eur
J Heart Fail. 15:1236–1244. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Katada E, Uematsu N, Takuma Y and
Matsukawa N: Comparison of effects of valsartan and amlodipine on
cognitive functions and auditory p300 event-related potentials in
elderly hypertensive patients. Clin Neuropharmacol. 37:129–132.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Manabe S, Okura T, Watanabe S, Fukuoka T
and Higaki J: Effects of angiotensin II receptor blockade with
valsartan on pro-inflammatory cytokines in patients with essential
hypertension. J Cardiovasc Pharmacol. 46:735–739. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang J, Jiang H, Yang J, Ding JW, Chen LH,
Li S and Zhang XD: Valsartan preconditioning protects against
myocardial ischemia-reperfusion injury through TLR4/NF-kappaB
signaling pathway. Mol Cell Biochem. 330:39–46. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schraufnagel DE and Schmid A: Pulmonary
capillary density in rats given monocrotaline. A cast corrosion
study. Am Rev Respir Dis. 140:1405–1409. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kopaliani I, Martin M, Zatschler B,
Bortlik K, Müller B and Deussen A: Cell-specific and
endothelium-dependent regulations of matrix metalloproteinase-2 in
rat aorta. Basic Res Cardiol. 109:4192014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guo RW, Yang LX, Wang H, Liu B and Wang L:
Angiotensin II induces matrix metalloproteinase-9 expression via a
nuclear factor-kappaB-dependent pathway in vascular smooth muscle
cells. Regul Pept. 147:37–44. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pullamsetti S, Krick S, Yilmaz H, Ghofrani
HA, Schudt C, Weissmann N, Fuchs B, Seeger W, Grimminger F and
Schermuly RT: Inhaled tolafentrine reverses pulmonary vascular
remodeling via inhibition of smooth muscle cell migration. Respir
Res. 6:1282005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
George J and D'Armiento J: Transgenic
expression of human matrix metalloproteinase-9 augments
monocrotaline-induced pulmonary arterial hypertension in mice. J
Hypertens. 29:299–308. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Frisdal E, Gest V, Vieillard-Baron A,
Levame M, Lepetit H, Eddahibi S, Lafuma C, Harf A, Adnot S and
Dortho MP: Gelatinase expression in pulmonary arteries during
experimental pulmonary hypertension. Eur Respir J. 18:838–845.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vieillard-Baron A, Frisdal E, Raffestin B,
Baker AH, Eddahibi S, Adnot S and D'Ortho MP: Inhibition of matrix
metalloproteinases by lung TIMP-1 gene transfer limits
monocrotaline-induced pulmonary vascular remodeling in rats. Hum
Gene Ther. 14:861–869. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zaidi SH, You XM, Ciura S, Husain M and
Rabinovitch M: Overexpression of the serine elastase inhibitor
elafin protects transgenic mice from hypoxic pulmonary
hypertension. Circulation. 105:516–521. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Long L, Crosby A, Yang X, Southwood M,
Upton PD, Kim DK and Morrell NW: Altered bone morphogenetic protein
and transforming growth factor-beta signaling in rat models of
pulmonary hypertension: Potential for activin receptor-like
kinase-5 inhibition in prevention and progression of disease.
Circulation. 119:566–576. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Thomas M, Docx C, Holmes AM, Beach S,
Duggan N, England K, Leblanc C, Lebret C, Schindler F, Raza F, et
al: Activin-like kinase 5 (ALK5) mediates abnormal proliferation of
vascular smooth muscle cells from patients with familial pulmonary
arterial hypertension and is involved in the progression of
experimental pulmonary arterial hypertension induced by
monocrotaline. Am J Pathol. 174:380–389. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Morrell NW, Upton PD, Kotecha S, Huntley
A, Yacoub MH, Polak JM and Wharton J: Angiotensin II activates MAPK
and stimulates growth of human pulmonary artery smooth muscle via
AT1 receptors. Am J Physiol. 277:L440–L448. 1999.PubMed/NCBI
|
